Venture Life Group PLC Director/PDMR Shareholding (5035O)
10 Giugno 2022 - 1:21PM
UK Regulatory
TIDMVLG
RNS Number : 5035O
Venture Life Group PLC
10 June 2022
10 June 2022
VENTURE LIFE GROUP PLC
("Venture Life", "VLG" or the "Company")
Director/PDMR Shareholding
Venture Life Group plc (AIM: VLG), a leader in developing,
manufacturing and commercialising products for the international
self-care market, announces that Paul McGreevy, Non-Executive
Chairman, today purchased 138,571 ordinary shares of 0.3p each in
the Company ("Ordinary Shares") at 35 pence per Ordinary Share.
Following this purchase, Mr Mcgreevy beneficially holds 287,439
Ordinary Shares representing approximately 0.23 per cent. of the
Company's issued share capital.
For further information, please contact:
Venture Life Group PLC +44 (0) 1344 578004
Jerry Randall, Chief Executive Officer
Daniel Wells, Chief Financial Officer
Cenkos Securities plc (Nomad and Joint Broker) +44 (0) 20 7397
8900
Stephen Keys / Camilla Hume (Corporate Finance)
Russell Kerr / Michael Johnson (Sales)
Singer Capital Markets (Joint Broker)
Shaun Dobson / Alaina Wong (Corporate Finance) +44 (0) 20
74963000
Jonathan Dighe (Sales)
About Venture Life ( www.venture-life.com )
Venture Life is an international consumer self-care company
focused on developing, manufacturing and commercialising products
for the global self-care market. With operations in the UK, Italy,
The Netherlands and Sweden, the Group's product portfolio includes
some key products such as the UltraDEX and Dentyl oral care product
ranges, the Balance Activ range in the area of women's intimate
healthcare, the Lift and Glucogel product ranges for hypoglycaemia,
Gelclair and Pomi-T for oncology support, products for fungal
infections and proctology, and dermo-cosmetics for addressing the
signs of ageing. Its products are sold in over 90 countries
worldwide.
The products, which are typically recommended by pharmacists or
healthcare practitioners, are available primarily through
pharmacies and grocery multiples. In the UK and The Netherlands
these are supplied direct by the company to retailers, elsewhere
they are supplied by the Group's international distribution
partners.
Through its two Development & Manufacturing operations in
Italy and Sweden, the Group also provides development and
manufacturing services to companies in the medical devices and
cosmetic sectors.
The Company makes the following disclosures in accordance with
article 19(3) of the Market Abuse Regulation:
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Paul McGreevy
-------------------------- ----------------------------------------
Reason for the notification
2
--------------------------------------------------------------------
a) Position/status Non-Executive Chairman
-------------------------- ----------------------------------------
b) Initial notification Initial notification
/Amendment
-------------------------- ----------------------------------------
Details of the issuer, emission allowance market participant,
3 auction platform, auctioneer or auction monitor
--------------------------------------------------------------------
a) Name Venture Life Group plc
-------------------------- ----------------------------------------
b) LEI 213800S8CZUPLAB2KC70
-------------------------- ----------------------------------------
Details of the transaction(s): section to be repeated
4 for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
--------------------------------------------------------------------
a) Description of the Ordinary Shares of 0.3p each in Venture
financial instrument, Life Group plc
type of instrument
Identification code GB00BFPM8908
-------------------------- ----------------------------------------
b) Nature of the transaction Purchase of ordinary shares
-------------------------- ----------------------------------------
c) Price(s) and volume(s) Volume Price
100,000 35.00p
-------
38,571 35.00p
-------
-------------------------- ----------------------------------------
d) Aggregated information 138,571 Ordinary Shares at a volume
weighted average price of 35.00 pence
per Ordinary Share
- Aggregated volume
- Price
-------------------------- ----------------------------------------
e) Date of the transaction 10 June 2022
-------------------------- ----------------------------------------
f) Place of the transaction London Stock Exchange
-------------------------- ----------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHFLFLLRAIILIF
(END) Dow Jones Newswires
June 10, 2022 07:21 ET (11:21 GMT)
Grafico Azioni Venture Life (LSE:VLG)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Venture Life (LSE:VLG)
Storico
Da Apr 2023 a Apr 2024
